CAR-T treatment does not increase AKI or death risk in patients with CKD

Sumary of CAR-T treatment does not increase AKI or death risk in patients with CKD:

  • Renal outcomes after chimeric antigen receptor T-cell (CAR-T) therapy: A single-center perspective.
  • Back to Healio Patients with chronic kidney disease are not at an increased risk for AKI or death after chimeric antigen receptor T-cell therapy, according to a speaker at ASN Kidney Week.
  • “A paucity of data exists of renal outcomes in patients treated with [chimeric antigen receptor T-cell] CAR-T, especially with CKD,” Rehan Ansari, MD, of Case Western Reserve University in Cleveland, and colleagues wrote.
  • “In conclusion, we also found a low incidence of AKI and CAR-T therapy, with no correlation with baseline renal function.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close